Form 4/A for VRDN Viridian Therapeutics, Inc.\DE
Accepted 2023-02-07 00:00:00 ET · period of report 2023-02-02 · accession 0000899243-23-004233 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DA | 2023-02-07 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | S - Sale+OE | $36.80 | -50.0K | 480.9K | -9% | -$1.84M |
| DA | 2023-02-07 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | M - OptEx | $0.15 | +50.0K | 530.9K | +10% | +$7,500 |
| DA | 2023-02-07 | 2023-02-02 | VRDN | Violin Jonathan | CEO, Dir | M - OptEx | $0.00 | -50.0K | 239.2K | -17% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-02-02 | S | D | 50,000 | $36.80 | 480,905 | D | — | — | (F2) This transaction was executed pursuant to a Rule 10b5-1 trading plan in multiple trades at prices ranging from $36.1523 to $37.3689. The price reported above reflects the weighted average sales price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. |
| 2 | Common | Common Stock | 2023-02-02 | M | A | 50,000 | $0.15 | 530,905 | D | — | — | |
| 3 | Derivative | Stock Option (Right to Buy) | 2023-02-02 | M | D | 50,000 | $0.00 | 239,205 | D | $0.15 · — to 2030-09-23 | 50,000 Common Stock | (F3) The option vested 25% on September 23, 2021 and then in equal monthly installments over the following 3 years, subject to the Reporting Person's continued service to Issuer through each vesting date. |